At Rush, we understand that being diagnosed with multiple myeloma can be overwhelming. But our experienced team will work with you to provide the most advanced care available for this rare blood cancer, along with supportive services that can help you preserve and maintain your quality of life.
Your care team at Rush will tailor your treatments to your unique symptoms and needs. Our multidisciplinary team includes hematologists, bone marrow transplant specialists, orthopedic surgeons, neurosurgeons, radiation oncologists, psychosocial oncologists and palliative care providers. Our clinic coordinator, Toreend Enecio, RN, will work closely with you to help coordinate your care every step of the way.
While multiple myeloma is not a curable disease, it is very treatable. And in the past decade, treatments have evolved and improved, allowing you to enjoy longer periods in remission.
As one of the top-ranked academic medical centers in the nation, Rush offers leading-edge treatments for multiple myeloma, including novel therapies, radiation therapy and immunotherapies. You’ll also have access to clinical trials that are looking at novel approaches, such as CAR-T cell therapy, for treating multiple myeloma.
Multiple myeloma support group
Rush has a multiple myeloma support group for patients and their families that is moderated by a social worker. The group meets quarterly on the third Friday of January, March, June and September at Rush University Medical Center. For more information about the support group, please contact us at (312) 563-2265.
Excellence in Multiple Myeloma Care
A highly experienced team
You’re in good hands at Rush when it comes to multiple myeloma expertise. Although multiple myeloma makes up just 1% of all cancers, our doctors and nurses treat large volumes of patients with this rare blood cancer. This level of expertise helps us determine the best treatments for you and how to successfully manage complications and side effects.
Effective pain management
Outstanding outcomes in stem cell transplant
Some patients may need a bone marrow or stem cell transplant as part of their multiple myeloma treatment. The Bone Marrow Transplant and Cellular Therapy program at Rush has excellent outcomes, with a 100% survival rate for the first 180 days after transplant.
Through clinical trials at Rush, CAR-T therapy may be available to certain patients who have multiple myeloma. This novel treatment uses patients’ own immune systems to treat the cancer.
Multiple myeloma is always preceded by monoclonal gammopathy of undetermined significance (MGUS), a rare blood condition. Rush’s MGUS clinic follows patients who are at risk of developing multiple myeloma and allows them to start treatment immediately if/when they develop multiple myeloma.
“We are dedicated to patient-centered care, which means our patients always come first. We provide state-of-the-art care to our patients, while also looking at them as a whole person. So our multidisciplinary team not only addresses our patients’ physical needs, but we also address their emotional and social needs.”
Agne Paner, MD
Director, Multiple Myeloma and Amyloidosis Program